- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilar Articles for the Week of October 5
Here are the top 5 biosimilar articles for the week of October 5, 2020.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of October 5, 2020.
Number 5: The European Medicines Agency has initiated review of a proposed ranibizumab biosimilar (SB11) from Samsung Bioepis.
Number 4:Of the 54 biosimilars approved by the European Medicines Agency (EMA) as of August 2019, fewer than half are available in Slovakia, but if the remaining 30 biosimilars were available, the nation’s health fund could save between €35 million and €50 million per year, according to a new study.
Number 3: A group of researchers from the biosimilar industry and academia have recommended in a review that the FDA widen the scope of acceptable studies for determining interchangeable status for biosimilars.
Number 2: According to a report from the IQVIA Institute for Human Data Science, biosimilars could generate sales of $80 billion over the next 5 years and potential biosimilar-generated health care savings could reach more than $100 billion during that same period.
Number 1: Accord brought 2 biosimilars referencing blockbuster oncology products to the United Kingdom and amended its agreement with Shanghai Henlius Biotech.
To read all of these articles and more, visit centerforbiosimilars.com.
Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab
January 14th 2025The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
January 11th 2025Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing partnership for a denosumab biosimilar, and 2 others join forces for an eculizumab biosimilar.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Equivalence Confirmed: CT-P41 Paves the Way for Affordable Osteoporosis Care
January 8th 2025Celltrion’s denosumab biosimilar demonstrated equivalent efficacy, safety, and immunogenicity compared with the originator in a phase 3 trial involving postmenopausal women with osteoporosis, paving the way for improved accessibility and cost savings in osteoporosis treatment.
